RAPIVAB Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rapivab, and what generic alternatives are available?
Rapivab is a drug marketed by Biocryst and is included in one NDA. There are three patents protecting this drug.
This drug has sixty-seven patent family members in twenty-eight countries.
The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. Additional details are available on the peramivir profile page.
DrugPatentWatch® Generic Entry Outlook for Rapivab
Rapivab was eligible for patent challenges on December 19, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 16, 2023. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for RAPIVAB
| International Patents: | 67 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 75 |
| Clinical Trials: | 2 |
| Patent Applications: | 1,781 |
| Drug Prices: | Drug price information for RAPIVAB |
| What excipients (inactive ingredients) are in RAPIVAB? | RAPIVAB excipients list |
| DailyMed Link: | RAPIVAB at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for RAPIVAB
Generic Entry Date for RAPIVAB*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for RAPIVAB
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| BioCryst Pharmaceuticals | Phase 3 |
| Department of Health and Human Services | Phase 4 |
| Johns Hopkins University | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for RAPIVAB
US Patents and Regulatory Information for RAPIVAB
RAPIVAB is protected by six US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of RAPIVAB is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting RAPIVAB
Antiviral treatments
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER
Antiviral treatments
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER
Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Antiviral treatments
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER
Antiviral treatments
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
Antiviral treatments
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RAPIVAB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RAPIVAB
See the table below for patents covering RAPIVAB around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20160129105 | 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS) | See Plans and Pricing |
| South Korea | 102323339 | See Plans and Pricing | |
| Germany | 69840674 | See Plans and Pricing | |
| Australia | 2013216632 | INTRAVENOUS ANTIVIRAL TREATMENTS | See Plans and Pricing |
| World Intellectual Property Organization (WIPO) | 2007117241 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
